The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs

Volk, H and Matiasek, L A and Feliu-Pascual, A L and Platt, S R and Chandler, K E (2008) The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. VETERINARY JOURNAL, 176 (3). pp. 310-319.

[img] Text
1732.pdf
Restricted to Repository staff only

Download (189kB)

Abstract

Twenty-two dogs with idiopathic epilepsy which were pharmacoresistant to phenobarbitone and bromide were treated with levetiracetam as an add-on medication. Records of eight dogs were used retrospectively to determine a safe, efficient levetiracetam dosage. Fourteen dogs were entered into a prospective, open label, non-comparative study. After 2 months of levetiracetam oral treatment (10 mg/kg TID), 8/14 dogs responded significantly to the treatment and seizure frequency was reduced by >= 50%. In dogs that remained refractory, the dosage was increased to 20 mg/kg TID for 2 months. One further dog responded to levetiracetam treatment. Levetiracetam, responders had a significant decrease in seizure frequency of 77% (7.9 +/- 5.2 to 1.8 +/- 1.7 seizures/month) and a decrease in seizure days per month of 68% (3.8 +/- 1.7 to 1.2 +/- 1.1 seizure days/month). However, 6/9 responders experienced an increase in seizure frequency and seizure days after 4-8 months continuing with the levetiracetam treatment at the last effective dosage. Levetiracetam was well tolerated by all dogs and sedation was the only side-effect reported in just one of the 14 dogs. (c) 2007 Elsevier Ltd. All rights reserved.